Abstracts tagged "Comorbidity"

Abstract Number: 1332 • ACR Convergence 2024
Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Amber Brown Keebler¹, Yunju Im², Sofia Pedro³, Ted Mikuls¹, Edward Peters¹ and Kaleb Michaud¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Often not evaluated in clinical visits, financial distress associated with medical costs, also known as financial toxicity, has emerged as an important factor affecting…
Abstract Number: 2388 • ACR Convergence 2024
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Katrina Williamson¹, Herbert Heien², Maria Stevens², Cynthia Crowson², Rozalina McCoy² and Ali Duarte-Garcia², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have been shown to have increased burden of multimorbidity. Racial disparities in multimorbidity have also been shown repeatedly.…
Abstract Number: 0409 • ACR Convergence 2024
Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Irene Chern¹, Jade Singleton², Xing Wang³ and Jordan Jones⁴, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Seattle Children's Hospital, Seattle, ³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Down syndrome (DS), a disorder caused by triplication of chromosome 21, affects around 1 in 1000 births making it one of the most common…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…
Abstract Number: 0481 • ACR Convergence 2024
Differential Effect of Comorbidities on the Clinical Evolution of Early Arthritis by Sex
Marina Dueñas¹, Juan Carlos Sáez¹, María Paula Álvarez², Patricia Quiroga¹, Maryia Nikitsina³, Rosario García-Vicuña², Ana Ortiz⁴, Isidoro González-Álvaro³ and Irene Llorente-Cubas⁴, ¹Servicio de Reumatología Hospital La Princesa, Madrid, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Madrid, Spain, ³University Hospital La Princesa, Madrid, Madrid, Spain, ⁴Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: The prevalence of comorbidities is increased in patients with rheumatoid arthritis (RA) compared to the general population1, but their impact in the earlier stages…
Abstract Number: 1340 • ACR Convergence 2024
Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease
Natalie Schanzer¹, Ted Mikuls², Bryant England², Katherine Wysham³, Jorge Rojas⁴, Sauer brian⁵, Beth Wallace⁶, Rachel Elam⁷, Andreas Reimold⁸, Gail Kerr⁹, John Richards¹⁰, Gary Kunkel¹¹, Iris Lee¹², Isaac Smith¹³, Paul Monach¹⁴, grant Cannon¹⁵ and Joshua Baker¹⁶, ¹Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Seattle VA, Mexico, Mexico, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷Augusta University, Evans, GA, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹¹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹²Washington University in St Louis, Saint Louis, MO, ¹³Duke University Hospital, Durham, NC, ¹⁴VA Boston Healthcare System, Boston, MA, ¹⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystalline arthritis that can both present alongside rheumatoid arthritis (RA) and, given its similar pattern of…
Abstract Number: 2612 • ACR Convergence 2024
Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Ana Cristina Medeiros-Ribeiro¹, Joao de Oliveira², Nadia Aikawa³, Sandra Pasoto², Leonard Kupa², Carla Goncalves Schahin Saad⁴, Luciana Parente², ANA PAULA ASSAD², Eduardo Borba², Emily Figueiredo Neves Yuki², Andrea Shimabuco⁴, Karina Bonfiglioli², Diogo Domiciano², Percival Sampaio-Barros⁴, Andre Franco², Julio Moraes⁵, Murillo Dorio², Claudia Goldenstein-Schainberg², Henrique Carriço Da Silva², Lucas Guimarães², Fernanda Chaer⁶, Caio Laguna Reis de Carvalho², Henrique Dalmolin², Clovis Silva⁷ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…
Abstract Number: 0718 • ACR Convergence 2024
Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic
Laura Ramos Ortiz de Zarate¹, Aresio Plaza Lopez², Alejandro mARTINEZ rODADO³, Maria Machattou¹, Pablo Navarro Palomo⁴, maria alonso de francisco³, Carlota Navarro Joven³, Natalia de la Torre-Rubio⁴, Olga Rusinovich⁵, Carolina Merino⁶, Blanca García Magallón⁷, Jose Campos Esteban⁷, hildegarda Godoy Tundidor⁸, Mónica Fernández Castro⁹, JESUS SANZ SANZ⁴, Carmen Barbadillo Mateos⁷, Carlos Maria Isasi Zaragoza⁷, Andrea Liso Andrino⁷, Maria Concepcion Sanchez Fernandez³ and Jose Luis Andreu⁴, ¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ²Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁵Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ⁷Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, ⁸Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ⁹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is often linked to previous viral infections. Clinical evidence suggests SARS-CoV-2 virus may follow a similar pattern, with an…
Abstract Number: 1347 • ACR Convergence 2024
Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
Manon Lesturgie-Talarek¹, Fabien Picard², sabrina hamroun³, Malika Saadi², Camille Macher⁴, Aude Deloumeau³, Karim Wahbi², jacques Blacher⁴, Yannick Allanore⁵ and Jérôme Avouac⁶, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Cardiology Department - Cochin Hospital, Paris, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Cardiology Department, Hôtel Dieu Hospital, Paris, France, ⁵Université Paris Cité, Paris, France, ⁶Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) mortality, linked to systemic inflammation and the presence of associated CV risk factors.…
Abstract Number: 0735 • ACR Convergence 2024
ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study
Sebastian Klapa¹, Henry Nording², Marlene Ludwig³, Sabrina Arnold⁴, Khalaf Kridin⁵, Anja Staehle⁶, Ralf Ludwig⁷ and Peter Lamprecht⁴, ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Cardioimmunology Research Group, Lübeck, Germany, ³Independent Researcher, Groß Grönau, Germany, ⁴University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ⁵5. Bar-Ilan University, Azrieli Faculty of Medicine, Safed, Israel, ⁶University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁷University of Lübeck, Lübeck Institute of Experimental Dermatology, Lübeck, Germany
Background/Purpose: In spite of significantly improved therapy during the last years, long-term morbidity and mortality has remained high in ANCA-associated vasculitis (AAV). The main causes…
Abstract Number: 1434 • ACR Convergence 2024
Prevalence of Liver Steatosis in Axial Spondyloarthritis : A Retrospective Study Using Computed Tomography Liver Minus Spleen Attenuation Ratio
Léa Da silva¹, olivier Fakih¹, mickael chouk¹, delphine weil-verhoeven², DANIEL WENDLING³, CLEMENT PRATI⁴ and FRANK VERHOEVEN¹, ¹Service de rhumatologie, CHU de Besancon, Besançon, France, ²Service d'hépatologie, CHU de Besancon, Besançon, France, ³University Hospital, Besançon, France, ⁴Service de Rhumatologie, centre hospitalier régional universitaire Jean-Minjoz, Université de Franche-Comté, Besançon, France
Background/Purpose: The management of axial spondyloarthritis (axSpA) comorbidities includes the metabolic syndrome (2). The latter includes steatotic liver disease (SLD) (3), which is present in…
Abstract Number: 0755 • ACR Convergence 2024
Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Anisha Dua¹, Andrea Rubbert-Roth², Kerri Ford³, Stefano Fiore⁴, Lita Araujo³, Timothy Beukelman⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Northwestern University Division of Rheumatology, Chicago, IL, ²Cantonal Hospital St Gallen, St Gallen, Switzerland, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Polymyalgia rheumatica (PMR), a common inflammatory rheumatic condition in people aged ≥50 years, is primarily treated with glucocorticoids (GC). Extended GC therapy can increase…
Abstract Number: 1602 • ACR Convergence 2024
Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients: A Nationwide Analysis
Faria Sami¹, Ahmad Basharat², Shahzad Ahmed Sami³ and Saman Tanveer⁴, ¹University of Alabama, Chicago, IL, ²Marshfield Clinic Health System, Marshfeild, WI, ³Trinity Health Oakland Hospital, Pontiac, ⁴John H. Stroger Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune vasculitis of small to medium blood vessels, often causing multisystemic complications leading to increased morbidity and…
Abstract Number: 0864 • ACR Convergence 2024
Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Michael Nevitt⁴, C.E. Lewis⁵, James Torner⁶ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴UCSF, Orinda, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Iowa, Iowa City
Background/Purpose: People with knee osteoarthritis (OA) and obesity (i.e. BMI ≥30kg/m2) have poorer function than those without obesity. However, function is not uniform among people…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].